These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 15853661)

  • 1. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG; Matts RL
    Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
    Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
    Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.
    Neckers L; Schulte TW; Mimnaugh E
    Invest New Drugs; 1999; 17(4):361-73. PubMed ID: 10759403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
    An WG; Schulte TW; Neckers LM
    Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geldanamycin and its anti-cancer activities.
    Fukuyo Y; Hunt CR; Horikoshi N
    Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L
    Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
    Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
    Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic target Hsp90 and cancer hallmarks.
    Miyata Y; Nakamoto H; Neckers L
    Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
    Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.
    Mahanta S; Pilla S; Paul S
    Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase.
    Stancato LF; Silverstein AM; Owens-Grillo JK; Chow YH; Jove R; Pratt WB
    J Biol Chem; 1997 Feb; 272(7):4013-20. PubMed ID: 9020108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
    Lawson B; Brewer JW; Hendershot LM
    J Cell Physiol; 1998 Feb; 174(2):170-8. PubMed ID: 9428803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.